Abstract:3038 Background: Non-small-cell lung cancer (NSCLC) is the leading cause of worldwide cancer-related deaths. Currently, ̃30-55% of the NSCLC patients develop recurrence due to minimal residual disease (MRD) after receiving surgical resection of the tumor. Therefore, there is an urgent clinical need to accurately predict the MRD risk in post-surgical NSCLC patients. However, the current targeted ctDNA mutation profiling method is limited by the cost of design and synthesis of patient-specific panels and relatively low sensitivity. Cell-free DNA (cfDNA) fragmentomics have recently shown great accuracy and affordability in early cancer detection. This retrospective study aims to develop an ultra-sensitive and affordable fragmentomic assay for MRD detection in NSCLC patients. Methods: A total of 116 NSCLC patients (54 stage I, 21 stage II, 40 stage III and 1 stage IV), who received curative surgical resections (32 patients relapsed during follow-up, median relapse time: 315.5 days), enrolled in the Lung Cancer Tempo-spatial Heterogeneity (LuCaTH) cohort. A total of 231 plasma samples, collected at 7 days post-surgery and 3 months thereafter, were used for whole-genome sequencings (̃5X). The cfDNA fragment size profile was used to fit a Regularized Cox Regression model. A leave-one-out cross-validation (LOOCV) was used to evaluate the model's predictive performance, and the optimal cutoff for predicting relapse was determined by identifying the Youden index to the predicted relative risk for all samples. Results: Our machine learning model showed an excellent performance in detecting patients with a high risk of recurrence. At 7 days post-surgery, the high-risk patients detected by our model showed an increased risk of 3 times compared to the low-risk patients (hazard ratio [HR] = 3.2, p < 0.001). Multivariate analysis confirmed that the association between model-determined high-risk status and patient relapses was not affected by the baseline clinical variables (age, sex, smoking, stage, etc.). Furthermore, the longitudinal analysis showed that our model was capable of detecting high-risk patients who were 11 times more likely to develop recurrence, independent from other clinical factors (multivariate HR = 11.8, p < 0.001). Overall, our model was able to identify high-risk status in 26 of 32 relapsed patients (81.2% sensitivity), preceding radiographic relapse by a median of 216 days. Furthermore, the sensitivity for MRD detection reached 91% while combining the model prediction with mutation-based ctDNA results. Conclusions: We have developed a predictive model for patient recurrence by detecting the fragmentomic profiling of plasma cfDNA contributed by the MRD. Despite being limited by the relatively small cohort size, our model has shown great sensitivity in predicting patient recurrence, therefore exhibiting a great potential to guide adjuvant therapy decisions.

Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer

Circulating Tumor DNA-minimal Residual Disease: an Up-and-coming Nova in Resectable Non-Small-cell Lung Cancer

Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments

Circulating Tumor DNA Minimal Residual Disease in Clinical Practice of Non-Small Cell Lung Cancer

Clinical Implications of Monitoring Circulating Tumor DNA in Early- and Late-Stage Non-Small Cell Lung Cancer Patients.

Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer

Circulating tumor DNA as markers of dynamic recurrence risk and adjuvant chemotherapy benefit in resected non-small cell lung cancer.

Postoperative Circulating Tumor DNA Can Refine Risk Stratification in Resectable Lung Cancer: Results from a Multicenter Study

Perioperative ctDNA-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)

Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detection of recurrence in early‐stage lung cancer

Dynamic ctDNA to inform the precise management of resected NSCLC: LUNGCA-2 study.

Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review

Circulating Tumor DNA Analyses as a Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer

Circulating Tumor DNA Clearance Predicts Prognosis Across Treatment Regimen in a Large Real-World Longitudinally Monitored Advanced Non-Small Cell Lung Cancer Cohort.

Utilization of cell-free DNA fragmentomics in minimal residual disease detection for non-small cell lung cancer.

Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer

Research Progress on Postoperative Minimal/Molecular Residual Disease Detection in Lung Cancer

Circulating Tumor DNA Analysis Depicts Subclonal Architecture and Genomic Evolution of Small Cell Lung Cancer

Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients

Potential Utility of Methylation Levels Detected from Circulating Tumor DNA (ctdna) in Predicting Molecular Residual Disease (MRD) in Patients with Resected Non-Small Cell Lung Cancer (NSCLC).

Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer